ReviewNature reviews. Drug discovery2013
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.
Review in Nature reviews. Drug discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine.Heliyon · 2024Review
- Functional Evaluation of 3D Liver Models Labeled with Polysaccharide Functionalized Magnetic Nanoparticles.Materials (Basel, Switzerland) · 2022Article
- Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology.Endocrinology · 2022Review
- Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.Clinical pharmacology and therapeutics · 2020Article
- The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology.Clinical pharmacology and therapeutics · 2020Review
- Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?Clinical pharmacology and therapeutics · 2020Review
- Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape.Biomarker insights · 2020Review
- Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial.Journal of diabetes and metabolic disorders · 2019Article
- Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow.Frontiers in pharmacology · 2019Review
- A pharmacogenetics approach to pain management.Neuropsychopharmacology reports · 2018Review
- The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2017Review
- Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies.Nucleic acids research · 2017Article
- Investigation of the Bioequivalence of Rosuvastatin 20 mg Tablets after a Single Oral Administration in Mediterranean Arabs Using a Validated LC-MS/MS Method.Scientia pharmaceutica · 2016Article
- The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).Pharmacogenomics · 2015Review
- Pharmacogenomic information in drug labels: European Medicines Agency perspective.The pharmacogenomics journal · 2015Review
- Pharmacogenetics and the print media: what is the public told?BMC medical genetics · 2015Article
- Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses.PloS one · 2015Article
- A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.Molecular cancer · 2014Article
- European Medicines Agency initiatives and perspectives on pharmacogenomics.British journal of clinical pharmacology · 2014Review
- CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.British journal of clinical pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetics, one of the cornerstones of personalized medicine, has the potential to change the way in which health care is offered by stratifying patients into various pretreatment categories, such as likely responders, likely non-responders or likely to experience adverse drug reactions. In order to advance drug development and regulatory science, regulatory agencies globally have promulgated guidelines on pharmacogenetics for nearly a decade. The aim of this article is to provide an overview of new guidelines for the implementation of pharmacogenetics in drug development from a multiregional regulatory perspective - encompassing Europe, the United States and Japan - with an emphasis on clinical pharmacokinetics.
Indexed as
Identifiers
23370249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.